TY - JOUR T1 - Cisplatin Augments FAS-mediated Apoptosis through Lipid Rafts JF - Anticancer Research JO - Anticancer Res SP - 2065 LP - 2071 VL - 30 IS - 6 AU - CHENG-RI HUANG AU - ZHE-XIONG JIN AU - LINGLI DONG AU - XIAO-PENG TONG AU - SUN YUE AU - TAKAFUMI KAWANAMI AU - TOSHIOKI SAWAKI AU - TOMOYUKI SAKAI AU - MIYUKI MIKI AU - HARUKA IWAO AU - AKIO NAKAJIMA AU - YASUFUMI MASAKI AU - YOSHIHIKO FUKUSHIMA AU - MASAO TANAKA AU - YOSHIMASA FUJITA AU - HIDEO NAKAJIMA AU - TOSHIRO OKAZAKI AU - HISANORI UMEHARA Y1 - 2010/06/01 UR - http://ar.iiarjournals.org/content/30/6/2065.abstract N2 - Cisplatin is widely and effectively used for the treatment of various types of cancer. However, its biochemical mechanisms are still unelucidated. Previously, we reported that membrane sphingomyelin (SM) was important for FAS-mediated apoptosis through lipid raft function. In this study, we strikingly show that cisplatin combined with CH11 (anti-FAS antibody, IgM) was able to induce marked apoptosis in SM synthase-restored WR/Fas-SMS1 cells, but not in SM synthase-deficient WR/FAS-SM(−) cells. In addition, we demonstrated that membrane SM played an important role in cisplatin/CH11-induced apoptosis through the classical caspase-dependent pathway, mainly by enhancing the formation of FAS-associated signaling complexes. ER -